FDA grants GEn-1123 rare disease designations for Duchenne muscular dystrophy

The FDA has granted orphan drug designation and rare pediatric disease designation to GEn-1123, an investigational oral small-molecule therapy being developed by GEn1E Lifesciences for Duchenne muscular dystrophy (DMD), according to a company announcement issued June 9, 2026.¹

“Receiving both Orphan Drug and Rare Pediatric Disease Designations for GEn-1123 marks important milestones for GEn1E and further supports our precision medicine approach to address rare and inflammatory diseases,” said Ritu Lal, PhD, founder and CEO of GEn1E Lifesciences, in the announcement.¹

DMD is a progressive, X-linked neuromuscular disorder caused by pathogenic variants in the DMD gene, leading to absent or markedly reduced dystrophin and progressive skeletal, respiratory, and cardiac muscle involvement.^2,3 The disease typically presents in early childhood, and management requires coordinated neuromuscular, rehabilitation, pulmonary, cardiac, endocrine, orthopedic, and psychosocial care.^2,3 Glucocorticoids remain a core disease-modifying therapy for many patients, while mutation-specific and dystrophin-targeted approaches are applicable only to selected populations and do not eliminate the need for comprehensive supportive care.^2,4

According to GEn1E, GEn-1123 is being developed as an oral “dual signal modulator” intended to affect inflammatory and degenerative processes implicated in DMD progression.¹ The company stated that the agent is designed to modulate proinflammatory signaling while supporting anti-inflammatory, prosurvival, and regenerative biology. ¹

The FDA grants orphan drug designation to therapies intended for rare diseases or conditions affecting fewer than 200,000 individuals in the United States. As described in the company announcement, the designation can confer development incentives, including potential tax credits for qualified clinical trials, exemption from certain FDA fees, and potential 7-year market exclusivity if the product is ultimately approved for the designated indication.¹

Rare pediatric disease designation applies to therapies intended for serious or life-threatening diseases that primarily affect individuals aged 18 years or younger and meet statutory rarity criteria. If a qualifying application for GEn-1123 were approved, the company may be eligible for a priority review voucher, subject to FDA requirements.¹

GEn1E described GEn-1123 as part of a pipeline developed through its GRID Platform, which the company said integrates patient endotyping, multiomics, biomarkers, and clinical data to guide therapeutic development.¹ The company also noted that its lead program, GEn-1124, is a separate small-molecule dual-signal modulator that has advanced to phase 2 development and received FDA Fast Track designation.¹

References

1. GEn1E Lifesciences. US FDA grants orphan drug and rare pediatric disease designations to GEn1E Lifesciences’ dual signal modulator for the treatment of Duchenne muscular dystrophy. Business Wire. Published June 9, 2026. Accessed June 9, 2026. https://www.businesswire.com/news/home/20260608752658/en/US-FDA-Grants-Orphan-Drug-and-Rare-Pediatric-Disease-Designations-to-GEn1E-Lifesciences-Dual-Signal-Modulator-for-the-Treatment-of-Duchenne-Muscular-Dystrophy

2. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251-267. doi:10.1016/S1474-4422(18)30024-3

3. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17(4):347-361. doi:10.1016/S1474-4422(18)30025-5

4. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol. 2018;17(5):445-455. doi:10.1016/S1474-4422(18)30026-7